| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Djenkolic acid does not have a specific defined pharmacological target. As a sulfur-containing amino acid analog, it may interact with amino acid transporters or enzymes involved in sulfur amino acid metabolism. The compound has been classified as an anti-infection compound in some databases, but specific molecular targets have not been identified.
|
|---|---|
| ln Vitro |
In vitro studies on Djenkolic acid are limited. As a sulfur-containing amino acid, it may affect cellular redox status and sulfur metabolism. The compound has been studied for its potential anti-infective properties. However, detailed in vitro pharmacological data, including IC50 values or specific biological activities, are not widely available in the literature.
|
| ln Vivo |
In vivo studies on Djenkolic acid are limited. The compound is a natural product found in Djenkol beans. Consumption of Djenkol beans has been associated with djenkolism, a condition characterized by renal toxicity due to the precipitation of Djenkolic acid crystals in the urinary tract. The compound has been studied for its toxicity rather than therapeutic applications.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Djenkolic acid are not well established. As a non-proteinogenic amino acid, it may interact with amino acid transporters or enzymes of sulfur amino acid metabolism. Standard binding assays could be performed to study interactions with cysteine transporters or enzymes such as cystathionine β-synthase, but such data are not available in the literature.
|
| Cell Assay |
In vitro cell-based assays for Djenkolic acid are limited. The compound may be tested in cell culture to assess its effects on cell viability, oxidative stress, or sulfur metabolism. However, specific experimental protocols for Djenkolic acid are not widely reported. As a natural product with potential toxicity, cytotoxicity assays may be relevant for studying its effects.
|
| Animal Protocol |
Djenkolic acid is a natural product, and in vivo animal studies are primarily focused on its toxicity. Animal models have been used to study the effects of Djenkolic acid on kidney function and crystal formation in the urinary tract. The compound has been associated with renal toxicity due to crystal precipitation. Detailed pharmacokinetic and pharmacodynamic studies are limited.
|
| ADME/Pharmacokinetics |
Djenkolic acid has a molecular weight of 254.33 and molecular formula C7H14N2O4S2. It is soluble in water. The compound has a melting point of approximately 325°C (rough estimate) and should be stored at 2-8°C. It is stable as a solid and can be stored for extended periods at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
After consuming acacia beans, acacia acid, which has low solubility under acidic conditions, can cause poisoning in humans. This amino acid precipitates as crystals, causing mechanical irritation to the renal tubules and urinary tract. (L1236) Djenkolic acid has been associated with djenkolism, a condition of renal toxicity caused by the precipitation of Djenkolic acid crystals in the urinary tract following consumption of Djenkol beans. The compound can cause acute kidney injury due to crystal nephropathy. Standard laboratory safety precautions should be followed when handling Djenkolic acid. |
| References | |
| Additional Infomation |
L-Dancholic acid is a dithioacetal composed of two L-cysteine molecules linked by a sulfhydryl group to a methylene group. It is both a plant metabolite and a toxin. It is a dithioacetal, a derivative of L-cysteine, and a non-protein L-α-amino acid. L-Dancholic acid has been reported in Euglena gracilis, Archidendron bubalinum, and plants in the Acacia genus, with relevant data available. Dancholic acid is a phytotoxic substance found in the pods of the Archidendron jiringa, a legume from Southeast Asia. It is nephrotoxic to humans. (L1236)
Djenkolic acid is a naturally occurring sulfur-containing amino acid found in Djenkol beans (Archidendron jiringa). It is structurally similar to cysteine and is classified as a non-proteinogenic amino acid. The compound is also known as S,S'-methylenebis-L-cysteine. It has been studied for its toxicity, particularly in relation to djenkolism, a condition characterized by renal toxicity due to crystal formation in the urinary tract. Djenkolic acid is not a drug and has no approved therapeutic indications. |
| Molecular Formula |
C7H14N2O4S2
|
|---|---|
| Molecular Weight |
254.31
|
| Exact Mass |
254.039
|
| CAS # |
498-59-9
|
| PubChem CID |
68134
|
| Appearance |
White to off-white solid powder
|
| Density |
1.501g/cm3
|
| Boiling Point |
515.4ºC at 760 mmHg
|
| Flash Point |
265.5ºC
|
| Vapour Pressure |
5.2E-12mmHg at 25°C
|
| Index of Refraction |
-65 ° (C=1, 1mol/L HCl)
|
| LogP |
0.634
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C([C@@H](C(=O)O)N)SCSC[C@@H](C(=O)O)N
|
| InChi Key |
JMQMNWIBUCGUDO-WHFBIAKZSA-N
|
| InChi Code |
InChI=1S/C7H14N2O4S2/c8-4(6(10)11)1-14-3-15-2-5(9)7(12)13/h4-5H,1-3,8-9H2,(H,10,11)(H,12,13)/t4-,5-/m0/s1
|
| Chemical Name |
3,3'-(Methylenedithio)dialanine
|
| Synonyms |
NSC76076L-Cysteine thioacetal of formaldehyde NSC 76076 Djenkolate NSC-76076Djenkolic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~25 mg/mL (~98.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9322 mL | 19.6610 mL | 39.3221 mL | |
| 5 mM | 0.7864 mL | 3.9322 mL | 7.8644 mL | |
| 10 mM | 0.3932 mL | 1.9661 mL | 3.9322 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
